L3VLUP
ProSign in

GKOS · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

GKOSLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • GKOS
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterGKOSLLY
Q3 20207 holders, $495m33 holders, $14.1bn
Q4 20206 holders, $742m29 holders, $17.3bn
Q1 20218 holders, $1.1bn24 holders, $23.0bn
Q2 20217 holders, $857m24 holders, $27.8bn
Q3 202111 holders, $539m31 holders, $29.9bn
Q4 202111 holders, $452m31 holders, $34.7bn
Q1 20228 holders, $622m24 holders, $35.3bn
Q2 20228 holders, $497m33 holders, $42.7bn
Q3 202211 holders, $492m31 holders, $43.4bn
Q4 20229 holders, $435m31 holders, $46.6bn
Q1 20239 holders, $510m33 holders, $44.3bn
Q2 20238 holders, $729m37 holders, $59.6bn
Q3 20237 holders, $551m44 holders, $67.6bn
Q4 20239 holders, $768m45 holders, $73.6bn
Q1 20246 holders, $1.1bn41 holders, $95.3bn
Q2 20247 holders, $1.4bn43 holders, $110bn
Q3 20247 holders, $1.5bn45 holders, $107bn
Q4 202410 holders, $1.9bn46 holders, $93.9bn
Q1 202510 holders, $1.3bn42 holders, $98.4bn
Q2 202510 holders, $1.6bn43 holders, $93.2bn
Q3 20259 holders, $736m39 holders, $86.7bn
Q4 20257 holders, $1.0bn41 holders, $123bn
Q1 20268 holders, $1.2bn39 holders, $106bn
Q2 20269 holders, $1.5bn44 holders, $132bn
GKOS

Glaukos Corp

Holders
8
Reported value
$1.2bn
Buyers
16
Sellers
10

Breadth +6 among 91 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
39
Reported value
$106bn
Buyers
25
Sellers
25

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 40 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only GKOS (1)

Farallon Capital Management LLC

Only LLY (32)

Acadian Asset Management LLC, AQR Capital Management LLC, ARK Investment Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), GAMCO Investors Inc, Harris Associates LP, Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, Point72 Asset Management LP, Polen Capital Management LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Soros Fund Management LLC, Squarepoint Ops LLC, and 7 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →